Bazedoxifene

DUAVIVE is indicated for the treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate. The experience treating women older than 65 years is limited.

, Dosing Considerations). 1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 2 Geriatrics Geriatrics (> 75 years of age): DUAVIVE has not been studied in women over 75 years of age, therefore DUAVIVE is not recommended for women over 75 years of age (see 14 CLINICAL TRIALS and 10 CLINICAL PHARMACOLOGY, Special Populations and Conditions, Geriatrics 2 CONTRAINDICATIONS • Active or past history of confirmed venous thromboembolism (such as deep vein thrombosis or pulmonary embolism) or active thrombophlebitis.

g. stroke, myocardial infarction, coronary heart disease). • Patients who are hypersensitive (for example, angioedema, anaphylaxis) to estrogens, bazedoxifene or to any ingredient in the formulation or component of the container. For a complete listing, see the